1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,310 | 0,331 | 14:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 11.12. | Tevogen Bio Inc: Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company's Shares of Common Stock | 5 | GlobeNewswire (USA) | ||
| 09.12. | Tevogen Bio Inc: Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine | 1 | GlobeNewswire (USA) | ||
| 08.12. | Tevogen Bio Inc: Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook | 6 | GlobeNewswire (USA) | ||
| TEVOGEN BIO Aktie jetzt für 0€ handeln | |||||
| 14.11. | Tevogen Bio Inc: Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q | 186 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended... ► Artikel lesen | |
| 14.11. | Tevogen Bio Holdings Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11. | Tevogen Bio Inc: Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID | 108 | GlobeNewswire (Europe) | This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk... ► Artikel lesen | |
| 03.11. | Tevogen Bio Inc: Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn | 113 | GlobeNewswire (Europe) | WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported... ► Artikel lesen | |
| 29.10. | Tevogen Bio Inc: Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress | 352 | GlobeNewswire (Europe) | WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore... ► Artikel lesen | |
| 15.10. | Tevogen Bio Inc: Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest | 342 | GlobeNewswire (Europe) | Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of... ► Artikel lesen | |
| 26.09. | Tevogen Bio Holdings verstößt gegen NASDAQ-Mindestkursanforderung | 4 | Investing.com Deutsch | ||
| 26.09. | Tevogen Bio Holdings Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 25.09. | Tevogen Bio Inc: Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell-Based Therapies with 100x PredicTcell Beta Data Expansion | 193 | GlobeNewswire (Europe) | Beta version of PredicTcell expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every... ► Artikel lesen | |
| 23.09. | Tevogen Bio Inc: Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID | 1 | GlobeNewswire (USA) | ||
| 19.09. | Tevogen Bio Inc: Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans | 1 | GlobeNewswire (USA) | ||
| 10.09. | Tevogen Bio Inc: Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston | 1 | GlobeNewswire (USA) | ||
| 09.09. | Tevogen Bio Inc: Tevogen Estimates 5-Year Top-Line Revenue of ~$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection | 149 | GlobeNewswire (Europe) | Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company")... ► Artikel lesen | |
| 08.09. | Tevogen announces $9-11 billion valuation for COVID-19 T cell therapy | 2 | Investing.com | ||
| 08.09. | Tevogen Bio Inc: Tevogen Values TVGN-489 at $9-$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell Allogeneic T Cell Platform | 222 | GlobeNewswire (Europe) | WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to... ► Artikel lesen | |
| 04.09. | Tevogen shares EBV treatment forecast with $3.5 billion revenue potential | 2 | Investing.com | ||
| 04.09. | Tevogen Bio Inc: Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas | 146 | GlobeNewswire (Europe) | The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could... ► Artikel lesen |
1 2 3 4 Weiter >>
80 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 38,600 | +0,40 % | QIAGEN N.V.: QIAGEN gibt Details zum Abschluss des synthetischen Aktienrückkaufs über bis zu rund $500 Mio. bekannt | Kapitalrückzahlung durch synthetischen Aktienrückkauf kombiniert schnelle, unmittelbare Kapitalrückzahlung an Aktionärinnen und Aktionäre mit einer Aktienzusammenlegung zur Steigerung des Gewinns... ► Artikel lesen | |
| AMGEN | 277,00 | +0,09 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,678 | -0,44 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 19,000 | 0,00 % | Laidlaw initiates coverage on Palatin Technologies stock with Buy rating | ||
| REGENERON PHARMACEUTICALS | 634,00 | -0,72 % | Alvotech, Teva reach settlement with Regeneron over Eylea biosimilar AVT06 in U.S. | ||
| INOVIO PHARMACEUTICALS | 2,060 | +1,98 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 1,560 | -3,11 % | COSCIENS Biopharma Inc. Announces Leadership Change | TORONTO, ONTARIO, Nov. 14, 2025 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,000 | +1,56 % | BioMarin übernimmt Amicus Therapeutics für 4,8 Milliarden US-Dollar | ||
| ARROWHEAD PHARMACEUTICALS | 57,06 | +0,56 % | Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch | ||
| XOMA ROYALTY | 21,600 | +0,93 % | XOMA Royalty Corporation Enters into Agreement to Acquire Generation Bio Co. | - Acquisition provides XOMA Royalty with potential milestone and royalty payments under Generation Bio's collaboration with Moderna - - Generation Bio's cell-targeted lipid nanoparticles (ctLNP) delivery... ► Artikel lesen | |
| PHIO PHARMACEUTICALS | 1,065 | 0,00 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762 | King of Prussia, Pennsylvania--(Newsfile Corp. - November 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its... ► Artikel lesen | |
| MOSAIC IMMUNOENGINEERING | - | - | Mosaic ImmunoEngineering Inc. - 10-Q, Quarterly Report | ||
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ORAGENICS | 0,825 | 0,00 % | ORAGENICS INC - 8-K, Current Report | ||
| LADRX | - | - | LadRx Corp - 8-K, Current Report |
Das Unternehmen TEVOGEN BIO HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,02 % bei einem Aktienkurs von 0,307 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TEVOGEN BIO HOLDINGS INC finden Sie auf Wallstreet Online.